Evidence map›Paper›PMID 15111553›Full record

SynthesisDiabetes care2004

A systematic review of adherence with medications for diabetes.

Joyce A Cramer

4 registry-linked trialsOpen access · bronzeAbstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Diabetes care, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 468 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
468citing papers in PubMed, 13 pooled it
20.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04841096 phase3completedstarted 2023, after this paper: background citation

Efficacy and Safety of the Oral Combined Therapy Glimepiride / Vildagliptin / Metformin in Patients With Type 2 Diabetes With Dual Treatment Failure

Ran2023Enrolled162Registered outcomes5Posted comparisons0ConditionsType 2 DiabetesArmsA1=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg), (A2) Glimepiride/Vildagliptin/Metformin, (B2) Glimepiride/Vildagliptin/Metformin, B2=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)
PMID 9585393PMID 32022600PMID 27088241PMID 24199686PMID 22246944PMID 30072404PMID 26775266PMID 28155046PMID 29405543PMID 31862745PMID 7589820PMID 26519337other papers from this trial
Open the trial in the graph
NCT03313960 phase4unknown statusnot on this mapstarted 2017, after this paper: background citation

A-One: A Randomized Controlled Trial Evaluating One Drop | Premium With Afrezza vs. One Drop | Premium Alone

TypeinterventionalSponsorInformed Data Systems, Inc.Ran2017 to 2019Enrolled400ConditionsDiabetes Mellitus, Type 2ArmsAfrezza plus One Drop, Premium, One Drop, Premium
NCT03376607 naunknown statusnot on this mapstarted 2019, after this paper: background citation

Community- and mHealth-Based Integrated Management of Diabetes in Primary Healthcare in Rwanda: The D²Rwanda Study

TypeinterventionalSponsorUniversity of AarhusRan2019 to 2021Enrolled209ConditionsDiabetes Mellitus, Telemedicine, Community Health WorkersArmsHBCP programme, mobile health application
NCT03711682 phase2 / phase3completednot on this mapstarted 2018, after this paper: background citation

Hypoglycemic Effect of Cinnamomum Verum in Type 2 Diabetic Patients in the Municipality of Comasagua

TypeinterventionalSponsorUniversidad Dr. José Matías DelgadoRan2018 to 2018Enrolled30ConditionsType 2 Diabetes MellitusArmsCinnamon, Wheat Flour
3 · Its place in the literature

Who cites it

468 citing papers in PubMed, 13 syntheses or guidelines pooled it, 1,207 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Efficacy ofDiabetes technology & therapeutics · 2020
    Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

408 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Joyce A CramerDepartment of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA. joyce.cramer@yale.edu
Yale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe purpose of this study was to determine the extent to which patients omit doses of medications prescribed for diabetes. RESEARCH DESIGN AND

methodsA literature search (1966-2003) was performed to identify reports with quantitative data on adherence with oral hypoglycemic agents (OHAs) and insulin and correlations between adherence rates and glycemic control. Adequate documentation of adherence was found in 15 retrospective studies of OHA prescription refill rates, 5 prospective electronic monitoring OHA studies, and 3 retrospective insulin studies.

resultsRetrospective analyses showed that adherence to OHA therapy ranged from 36 to 93% in patients remaining on treatment for 6-24 months. Prospective electronic monitoring studies documented that patients took 67-85% of OHA doses as prescribed. Electronic monitoring identified poor compliers for interventions that improved adherence (61-79%; P < 0.05). Young patients filled prescriptions for one-third of prescribed insulin doses. Insulin adherence among patients with type 2 diabetes was 62-64%.

conclusionsThis review confirms that many patients for whom diabetes medication was prescribed were poor compliers with treatment, including both OHAs and insulin. However, electronic monitoring systems were useful in improving adherence for individual patients. Similar electronic monitoring systems for insulin administration could help healthcare providers determine patients needing additional support.

Indexed as

Patient ComplianceDiabetes MellitusDiabetes Mellitus, Type 2HumansHypoglycemic AgentsRetrospective StudiesHypoglycemic Agents

Identifiers

PMID15111553
OpenAlexW2164733897

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.